PFI Q2 financials
This article was originally published in The Tan Sheet
Executive Summary
Two long-term supply agreements with drug companies, in addition to spring launch of generic ibuprofen-pseudoephedrine (Whitehall's Advil Cold & Sinus), should "significantly enhance sales and earnings over the next two to three years," private labeler says Feb. 13. Sales for fiscal second quarter ended Dec. 29 rose 8.4% to $12.9 mil., with quarterly loss of $2.9 mil. For the six months, sales edged up 4% to $26.1 mil., with net loss of $4.9 mil...